Trial Profile
A Phase 1, Open-Label, Randomized, Two-Period, Two-Sequence Crossover Study to Assess the Effect of Food on the Pharmacokinetics of a Single 30 mg Tablet of Apremilast (CC-10004) in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Apr 2021
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Ankylosing spondylitis; Behcet's syndrome; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Amgen
- 12 Jul 2012 New trial record